期刊文献+

吉西他滨联合顺铂或氟尿嘧啶治疗晚期胰腺癌临床疗效的比较 被引量:6

Comparative Study of Gemcitabine Plus Cisplatin and Gemcitabine Plus Fluorouracil in the Treatment of Advanced Pancreatic Cancer
下载PDF
导出
摘要 目的 比较GP方案 (吉西他滨 +顺铂 )与GF方案 (吉西他滨 +氟尿嘧啶 )治疗晚期胰腺癌的近期疗效和毒副作用。方法 经病理组织学或细胞学检查证实的 60例胰腺癌患者 ,随机分为GP组和GF组 ,各 3 0例。GP组给予吉西他滨 10 0 0mg/m2加生理盐水 10 0ml,静脉滴注 3 0min ,第 1、8、15天 ;顺铂 40mg ,静脉滴注 ,第 15、16、17天。GF组给予吉西他滨 10 0 0mg/m2 加生理盐水 10 0ml ,静脉点滴 3 0min ,第 1、8、15天 ;氟尿嘧啶 5 0 0mg/m2 加 5 %GS 5 0 0ml ,静脉滴注时间超过 6h ,第 1~ 5天。结果 GP组PR 3例 ,MR 5例 ,NC 12例 ,PD 5例 ,PR +MR为 3 2 .0 % ,中位生存期为 8.7个月 ,临床受益反应率 (CBR )为 5 7.7% (15 /2 6) ,CA 19 9水平下降超过 5 0 %者达 48.1% (13 /2 7)。GF组PR 3例 ,MR 8例 ,NC 9例 ,PD 4例 ,PR +MR为 45 .8% ,中位生存期为 10 .1个月 ,CBR 82 .1% (2 3 /2 8) ,CA19 9水平下降超过 5 0 %者达 5 3 .6% (15 /2 8)。 2组比较 ,CBR有显著性差异 (P <0 .0 5 ) ,GF疗效较佳。不良反应主要为白细胞减少和血小板减少 ,2组无显著性差异。结论 含吉西他滨的联合化疗方案与以往单药方案比较 ,疗效高、副作用小、患者中位生存期长 ,临床受益反应率 (CBR )高 ;GP方案和GF方案比较 ,后者CBR更高 Objective To compare the efficacy and toxicity of Gemcitabine plus Cisplatin and Gemcitabine plus Fluorouracil in the treatment of advanced pancreatic cancer.Methods Sixty patients with advanced pancreatic cancer were randomly divided into GP group(Gemcitabine+Cisplatin,30 cases) and GF group(Gemcitabine+Fluorouracil,30 cases).All patients were treated with Gemcitabine in dose of 1 000 mg/m 2(diluted in 100 ml saline solution over 30 minutes) once a week for 3 consecutive weeks.Group GP was followed by Cisplatin 40 mg,intravenous drip on day 15,16,17.Group GF was followed by 5-Fu 500 mg/m 2(diluted in 5%GS 500 ml,ivd,over 6 hours) every day for the first five days.Results In group GP,8 cases(32.0%) were PR and MR,the median survival time was 8.7 months,Clinical Beneficial Rate(CBR) was 57.7%,and CA19-9 decreased by over 50% in 13 cases(48.1%).In group GF,11 cases(45.8%) were PR and MR,the media survival times was 10.1 months,CBR was 82.1%,and CA19-9 decreased by over 50% in 15 cases(53.6%).There was significant difference in CBR between the two groups(P<0.05).The main toxicities were leukopenia and thrombocytopenia.Conclusion GP or GF is a feasible and well-tolerated cheomtherapy regimen in treating of advanced pancreatic cancer with a better therapeutic efficacy and few side effect.The median survival period is long and CBR is high,especially with GF regimen.
出处 《实用癌症杂志》 2003年第5期527-530,共4页 The Practical Journal of Cancer
关键词 吉西他滨 顺铂 氟尿嘧啶 治疗 晚期 胰腺癌 Gemcitabine Cisplatin Fluorouracil Chemotherapy Pancreatic cancer
  • 相关文献

参考文献12

  • 1周际昌主编..实用肿瘤内科学[M].北京:人民卫生出版社,1999:639.
  • 2吴娜,梁晓丽.健择[J].中国新药杂志,2000,9(3):204-205. 被引量:45
  • 3夏穗生 黄光英 张良华.肿瘤临床诊疗指南[M].北京:北京科技出版社,1999.368-370. 被引量:3
  • 4谷跣之 哈献文 宋少章.肿瘤放射治疗学[M].北京:北京医科大学中国协和医科大学联合出版社,1993.500. 被引量:3
  • 5Richard P, Lawrence RC, William J H, et al. Cancer management: a multidisciplinary approach[ M] sixth edition.Melville, NY: PRR, Inc. 2001 : 249-- 250. 被引量:1
  • 6Hoffman JP,Lipsitz S,Pisansky T,et al. Phase Ⅱ trial of preoperative radiation therapy and chemotherapy for patients with localized, respectable adenocareinoma of the pancreas :An Eastern Cooperative Oncology Group Study[J] .J Clin Oncol, 1998,16(1) :317. 被引量:1
  • 7Klein B, Sadikov E. Comparison of 5-Fu and leucovorin to gemcitabine in the treatment of pancreatic cancer[J ].Oncol Rep,2000,7(4) :875. 被引量:1
  • 8Rothenberg ML, Moore MJ, Cripps MC, et al. A phaseⅡ trial of gemcitabine in patients with 5-Fu refractory pancreas cancer [J]. Ann Oncol, 1996,7(4) : 347. 被引量:1
  • 9Berlin J, Voi M, Alberti D, et al. Phase I trial of gemcitabine,leucovorin and 5-fluorouracil in patients with advanced malignancy [J ]. Proc Annu Meet Am Soc Clin Oncol, 1997,16A(2) :724. 被引量:1
  • 10Halm U,Schumann T. Decrease of CA19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer[J ]. Br J Cancer,2000,82(5) : 1013. 被引量:1

共引文献54

同被引文献78

引证文献6

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部